[Use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products]
从仂于仂亟于仂 仗仂 亳仗仂仍亰仂于舒仆亳 亳仂亟仆 仄舒亠亳舒仍仂于 亳 仗仂仄亠亢仂仆 仗仂亟从仂于, 仗仂仍亠仆仆 亳亰 舒亰仍亳仆 亳仂仆亳从仂于, 于 仗仂亳亰于仂亟于亠 仆亠亠从仂仄弍亳仆舒仆仆 弍亳仂仍仂亞亳亠从亳 仍亠从舒于亠仆仆 仗亠仗舒舒仂于
Biotherapy Drug Circulation Regulation in the Republic of Belarus. Current Status and Long-Term Prospects
Illustrates the current norms in place in Belorussia for the marketing authorization of pharmaceutical products and the dossier requirements for biotherapeutics & biosimilars
[Guideline on Comparability of Biotechnology-derived Medicinal Products After a Change in The Manufacturing Process Non-clinical and Clinical Issues]
从仂于仂亟于仂 仗仂 仂仗仂舒于亳仄仂亳 弍亳仂亠仆仂仍仂亞亳亠从亳 仍亠从舒于亠仆仆 仗亠仗舒舒仂于 仗仂仍亠 亳亰仄亠仆亠仆亳 仗仂亠舒 仗仂亳亰于仂亟于舒: 亟仂从仍亳仆亳亠从亳亠 亳 从仍亳仆亳亠从亳亠 于仂仗仂
19. 亢亠仆亠亳从亳: 从于亳于舒仍亠仆仆仂
仂亞亟舒 仆亢仆仂 仂仗亠亟亠仍 弍亳仂从于亳于舒仍亠仆仆仂?
仆仂于仆仂亶 仗仂从舒亰舒亠仍 舒于仆亳亠仍仆仂亶 仂亠仆从亳
仗舒亠仆亠舒仍仆 亟亢亠仆亠亳从仂于 亠舒仗亠于亳亠从舒
从于亳于舒仍亠仆仆仂 仂亳亞亳仆舒仍仆仄 仗亠仗舒舒仂仄, 仗仂仍亠仆仆舒
于 舒于仆亳亠仍仆 从仍亳仆亳亠从亳 亳仍亠亟仂于舒仆亳 ()
=
Guidance for Industry Bioequivalence Recommendations for Specific Products. U.S. Department of Health and Human Services Food and
Drug Administration Center for Drug Evaluation and Research (CDER). June 2010. Available on:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory- Information/Guidances/ucm072872.pdf